



Healthcare Distribution Alliance

PATIENTS MOVE US.

November 30, 2020

Aryan Showers  
Director, Office of Policy and Accountability  
Runnels Building  
1190 South S. Francis Drive  
Santa Fe, NM 87505

**Re: Wholesale Prescription Drug Importation Program Public Hearing**

Ms. Showers,

The Healthcare Distribution Alliance (HDA) offers this response to communicate our concern with the State of New Mexico regarding the Wholesale Prescription Drug Importation Act, 26-4-1 to 26-4-10 NMSA 1978, enacted through Senate Bill 1. Specifically, HDA is seeking clarity and a better understanding of the role of vendors in the Program.

HDA is the national trade association representing primary pharmaceutical wholesale distributors — the vital link between the nation’s pharmaceutical manufacturers and more than 200,000 pharmacies and other healthcare settings nationwide. Specific to New Mexico, our members serve over 1,500 pharmacy customers across the state.

On behalf of the industry, HDA engaged throughout the legislative process, outlining the complex issues associated with SB 1. We remain concerned that the Wholesale Prescription Drug Importation Act will negatively impact the pharmaceutical supply chain and jeopardize patient safety.

The U.S. pharmaceutical supply chain is the most sophisticated, efficient and secure drug supply chain system in the world. The highly secure nature of the supply chain was further strengthened in 2013 by the passage of the federal Drug Supply Chain Security Act (DSCSA). This law outlines steps to build an electronic, interoperable system to identify and trace prescription drugs as they are distributed in the United States. DSCSA enhances the Food and Drug Administration’s (FDA) ability to help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated or otherwise harmful. The system also improves detection and removal of potentially dangerous drugs from the pharmaceutical supply chain.

Under the confines of DSCSA, any drug distributed in the U.S. must be distributed to and from an authorized trading partner. Further, any drug distributed within the U.S. must also be a serialized product, incorporating the National Drug Code, Serial Number, Lot Number and expiration date. Medications that are sold or designated for sale in Canada as well as other countries do not conform with these U.S. traceability regulations and do not have the necessary data to align with DCSCA requirements, increasing the risk of illegitimate or counterfeit medications entering the U.S. market and putting patient safety at risk. As the FDA continues to finalize its regulatory guidance for the second

phase of DSCSA implementation, it is counterproductive to introduce foreign pharmaceuticals—that would need repackaging, relabeling and serialization as well as screening for counterfeiting—before the current supply chain is able to conform and comply with new DSCSA standards.


Drug approval by the FDA is contingent upon the strictest guidelines for product integrity, good manufacturing practices, scientific data analysis and public safety. At this point, the FDA cannot guarantee to American consumers that a drug sold or designated for sale in foreign countries will be the same product his or her physician prescribed, nor can it fully attest to its safety.<sup>1</sup> Further, the four former FDA Commissioners wrote an open letter to Congress in March 2017 expressing their continued concerns with any drug importation program.<sup>2</sup>

Both branded and generic drugs are susceptible to counterfeiting, sometimes containing insufficient or too much of an active ingredient or being contaminated by unsanitary manufacturing conditions. The U.S. supply chain, regulated by the FDA, devotes significant resources to ensure safe manufacturing, product authenticity and the secure distribution of drugs through authorized parties from the point of manufacture to the point of dispensing. HDA members are an essential part of this closed distribution system, working daily with supply chain partners, law enforcement and government regulators to help ensure prescription medicines are safely delivered to licensed pharmacies within the U.S.

HDA appreciates the inclusion of requirements for safety and DSCSA traceability standards in the law. However, these provisions are moot under current federal law. When comparing the current structure and standards of the U.S. pharmaceutical supply chain with international standards, HDA does not see how meeting such requirements is possible. Verifying and tracking foreign product in the U.S. pharmaceutical supply chain to ensure patient safety and prevent diversion by the strict standards put forth within current federal law would be impossible.

In moving forward with the enactment of the Wholesale Prescription Drug Importation Act, the New Mexico Department of Health must understand the risks associated with establishing an importation program, specifically the risks it is asking potential vendors contracted under the Program to assume with the inherent uncertainty that exists. While the current proposal lacks detail in how the program will be operationalized, HDA

Sincerely,



Leah Lindahl

Senior Director, State Government Affairs  
Healthcare Distribution Alliance

---

<sup>1</sup> Letter from William K. Hubbard, Associate Commissioner for Policy and Planning, FDA to Robert P. Lombardi, Esq., The Kullman Firm <https://www.crowell.com/pdf/FDAletter.pdf>

<sup>2</sup> Open letter to Congress authored by four FDA commissioners opposing drug importation, (March 2017) [https://www.documentcloud.org/documents/3519007-FDA-Commissioners-Drug-Reimportation.html?utm\\_source=newsletter&utm\\_medium=email&utm\\_campaign=newsletter\\_axiosvitals](https://www.documentcloud.org/documents/3519007-FDA-Commissioners-Drug-Reimportation.html?utm_source=newsletter&utm_medium=email&utm_campaign=newsletter_axiosvitals)